What’s Next for Achaogen, Inc. (AKAO) After Today’s Significant Increase?

April 21, 2018 - By Richard Conner

Achaogen, Inc. (NASDAQ:AKAO) Logo

Investors sentiment increased to 1.32 in Q4 2017. Its up 0.16, from 1.16 in 2017Q3. It increased, as 16 investors sold Achaogen, Inc. shares while 21 reduced holdings. 22 funds opened positions while 27 raised stakes. 29.75 million shares or 6.36% less from 31.77 million shares in 2017Q3 were reported.
Bnp Paribas Arbitrage invested in 7,287 shares. Deutsche State Bank Ag holds 0% or 517,221 shares in its portfolio. Timessquare Cap Mngmt Limited Liability Company reported 0.1% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO). Harbourvest Prns Lc has 0.17% invested in Achaogen, Inc. (NASDAQ:AKAO) for 20,000 shares. 92,949 are owned by Citigroup. 677 are owned by Royal Commercial Bank Of Canada. 376,021 are owned by Northern Corp. Jpmorgan Chase Com holds 0% in Achaogen, Inc. (NASDAQ:AKAO) or 11,070 shares. Renaissance Technologies Ltd Com has invested 0.01% in Achaogen, Inc. (NASDAQ:AKAO). 294,718 were accumulated by Geode Management Lc. Moreover, Nea Co has 2.32% invested in Achaogen, Inc. (NASDAQ:AKAO). Parallax Volatility Advisers Lp holds 0% or 5,308 shares. Contravisory Management stated it has 27 shares or 0% of all its holdings. Group Inc One Trading Lp accumulated 0.01% or 94,980 shares. Ny State Common Retirement Fund reported 32,500 shares.

Since December 18, 2017, it had 9 insider buys, and 5 insider sales for $10.50 million activity. The insider DUGGAN ROBERT W bought 36,300 shares worth $403,712. Schilke Tobin sold 1,108 shares worth $11,822. The insider Wise Blake sold 1,640 shares worth $17,499. Hillan Kenneth J. also sold $32,109 worth of Achaogen, Inc. (NASDAQ:AKAO) shares.

The stock of Achaogen, Inc. (NASDAQ:AKAO) is a huge mover today! The stock increased 2.88% or $0.375 during the last trading session, reaching $13.385. About 1.18 million shares traded or 0.33% up from the average. Achaogen, Inc. (NASDAQ:AKAO) has declined 41.74% since April 21, 2017 and is downtrending. It has underperformed by 53.29% the S&P500.
The move comes after 5 months positive chart setup for the $598.65M company. It was reported on Apr, 21 by Barchart.com. We have $13.79 PT which if reached, will make NASDAQ:AKAO worth $17.96 million more.

Analysts await Achaogen, Inc. (NASDAQ:AKAO) to report earnings on May, 14. They expect $-0.92 EPS, down 80.39 % or $0.41 from last year’s $-0.51 per share. After $-0.98 actual EPS reported by Achaogen, Inc. for the previous quarter, Wall Street now forecasts -6.12 % EPS growth.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 6 analysts covering Achaogen (NASDAQ:AKAO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Achaogen had 7 analyst reports since October 24, 2017 according to SRatingsIntel. Mizuho maintained it with “Buy” rating and $28.0 target in Wednesday, February 28 report. As per Thursday, November 9, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Needham with “Buy” on Wednesday, February 28. The rating was maintained by Wedbush on Wednesday, February 14 with “Buy”. The stock of Achaogen, Inc. (NASDAQ:AKAO) earned “Buy” rating by Stifel Nicolaus on Wednesday, February 28. On Tuesday, January 2 the stock rating was maintained by Cowen & Co with “Buy”.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $598.65 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.